TRAFFIC ENGINEERING STUDIES Clause Samples

The "Traffic Engineering Studies" clause establishes the requirement for conducting analyses to assess and optimize traffic flow and safety within a specific area or for a particular project. Typically, this involves gathering data on current traffic patterns, evaluating the impact of proposed changes such as new developments or road modifications, and recommending solutions like signal adjustments or signage improvements. The core function of this clause is to ensure that any changes to infrastructure are informed by data-driven insights, thereby minimizing congestion, enhancing safety, and supporting efficient transportation planning.
TRAFFIC ENGINEERING STUDIES. The ENGINEER shall conduct traffic signal studies for designated locations or sections of roadways for use in authorizing traffic signals and other recommendations for improving traffic operations. The study will contain the following: • Perform manual turning movement counts at the study location during a weekday (Tuesday, Wednesday or Thursday) for the following periods: 6:00 – 9:00 a.m., 9:30 – 11:30 a.m., 12:00 – 1:30 p.m., 2:00 – 3:30 p.m., and 4:00-6:00 p.m. Counts will be recorded at 15 minute and hourly intervals. Totals will be provided for the a.m. and p.m. periods along with the overall 12 hours. • Perform 24 hour traffic counts (15 minute and hourly intervals) when requested at the study location or section of roadway. • Perform pedestrian volume counts on each approach at the study location for the time periods mentioned above or as directed by the STATE. • Conduct a site inspection at the study location and record traffic characteristics observed in the field. The field work may include taking measurements, locating utilities, locating existing signal equipment, identifying existing conditions and taking digital photographs of the intersection (minimum of three photographs per approach). • Prepare condition diagram showing details from site inspection and field work mentioned above. • Obtain and analyze accident records for the study location or section of roadway from the STATE or local governmental agency during the most recent thirty six
View SourceView Similar (8)
TRAFFIC ENGINEERING STUDIES. DocuSign Envelope ID: 0933C901-0823-45FC-BEC7-5D94131D729B DocuSign Envelope ID: 0933C901-0823-45FC-BEC7-5D94131D729B PeopleSoft Contract No. 7650 Legacy Contract No. 12-7IDP5014 The Engineer shall conduct traffic signal studies for designated locations or sections of roadways for use in authorizing traffic signals and other recommendations for improving traffic operations. At a minimum, the Engineer shall include study results for the following activities. Engineer shall: • Perform manual turning movement counts at the study location during a weekday (Tuesday, Wednesday or Thursday) for the following periods: 6:00 – 9:00 a.m., 9:30 – 11:30 a.m., 12:00 – 1:30 p.m., 2:00 – 3:30 p.m., and 4:00-6:00 p.m. Record counts will be recorded at 15 minute and hourly intervals. Provide totals for the a.m. and p.m. periods along with the overall 12 hours. • Perform 24 hour traffic counts (15 minute and hourly intervals) when requested at the study location and/or section of roadway. • Perform pedestrian volume counts on each approach at the study location for the time periods mentioned above or as directed by the State. • Conduct a site inspection at the study location and record traffic characteristics observed in the field. Inspection includes taking measurements, locating utilities, locating existing signal equipment, identifying existing conditions, and taking digital photographs of the intersection (minimum of three photographs per approach). • Prepare condition diagram showing details from site inspection and filed work mentioned above. • Obtain and analyze accident records for the study location or section of roadway from the State or local governmental agency during the most recent 36 month period. • Prepare collision diagram from accident records showing crash experience by type, location, direction of movement, severity, weather, time of day, and date. • Prepare a site map of the study area. The site map must include existing control devices at the intersection and all existing signals for the area specified by the State. • Analyze all collected traffic and pedestrian count data and complete the latest version of the Traffic Survey County Analysis form for inclusion in the report. • Prepare and submit two reports to the State, which summarizes the findings of the traffic and pedestrian counts and field inventories for each location. The reports must include existing condition diagrams, field photographs, traffic counts, and any recommended improvements. The E...
View SourceView Similar (2)
TRAFFIC ENGINEERING STUDIES. The Engineer shall conduct traffic signal studies for designated locations or sections of roadways for use in authorizing traffic signals and other recommendations for improving traffic operations. The Engineer shall perform the following: • Perform manual turning movement counts at the study location during a weekday (Tuesday, Wednesday or Thursday) for the following periods: 6:00 – 9:00 a.m., and 4:00- 7:00 p.m. Counts will be recorded at 15 minute and hourly intervals. Totals will be provided for the a.m. and p.m. periods. • Perform 24 hour traffic counts (15 minute and hourly intervals) when requested at the study location and neccessary section of roadway. • Conduct a site inspection at the study location and record traffic characteristics observed in the field. The file work may include taking measurements, locating utilities, locating existing signal equipment, identifying existing conditions and taking digital photographs of the intersection (minimum of three photographs per approach). • Prepare condition diagram showing details from site inspection and filed work mentioned above. • Obtain and analyze accident records for the study location or section of roadway from the State or local governmental agency during the most recent thirty six (36) month period. • Prepare collision diagram from accident records showing crash experience by type, location, direction of movement, severity, weather, time of day and date. • Prepare a site map of the area where the study is requested. Information shall consist of existing control devices at the intersection and existing signals for one mile. • Prepare and submit two (2) reports, to the State, which summarizes the findings of the traffic and pedestrian counts and field inventories for each location. The reports shall DocuSign Envelope ID: 0EF7DD01-5DEF-492D-AF48-72F6373D49D2 DocuSign Envelope ID: 973D3771-56AD-4A37-8E90-25E408E93E1A include existing condition diagrams, field photographs, traffic counts, and recommended improvements. The Engineer shall address the State’s review comments.
View Source
TRAFFIC ENGINEERING STUDIES. Traffic Signal Timing
View Source

Related to TRAFFIC ENGINEERING STUDIES

  • Clinical Studies The animal and other preclinical studies and clinical trials conducted by the Company or on behalf of the Company were, and, if still pending are, to the Company’s knowledge, being conducted in all material respects in compliance with all Applicable Laws and in accordance with experimental protocols, procedures and controls generally used by qualified experts in the preclinical study and clinical trials of new drugs and biologics as applied to comparable products to those being developed by the Company; the descriptions of the results of such preclinical studies and clinical trials contained in the Registration Statement and the Prospectus are accurate and complete in all material respects, and, except as set forth in the Registration Statement and the Prospectus, the Company has no knowledge of any other clinical trials or preclinical studies, the results of which reasonably call into question the clinical trial or preclinical study results described or referred to in the Registration Statement and the Prospectus when viewed in the context in which such results are described; and the Company has not received any written notices or correspondence from the FDA, the EMA, or any other domestic or foreign governmental agency requiring the termination, suspension or modification of any preclinical studies or clinical trials conducted by or on behalf of the Company that are described in the Registration Statement and the Prospectus or the results of which are referred to in the Registration Statement and the Prospectus.

  • Clinical 1.1 Provides comprehensive evidence based nursing care and individual case management to a specific group of patients/clients including assessment, intervention and evaluation. 1.2 Undertakes clinical shifts at the direction of senior staff and the Nursing Director including participation on the on-call/after-hours/weekend roster if required. 1.3 Responsible and accountable for patient safety and quality of care through planning, coordinating, performing, facilitating, and evaluating the delivery of patient care relating to a particular group of patients, clients or staff in the practice setting. 1.4 Monitors, reviews and reports upon the standard of nursing practice to ensure that colleagues are working within the scope of nursing practice, following appropriate clinical pathways, policies, procedures and adopting a risk management approach in patient care delivery. 1.5 Participates in ▇▇▇▇ rounds/case conferences as appropriate. 1.6 Educates patients/carers in post discharge management and organises discharge summaries/referrals to other services, as appropriate. 1.7 Supports and liaises with patients, carers, colleagues, medical, nursing, allied health, support staff, external agencies and the private sector to provide coordinated multidisciplinary care. 1.8 Completes clinical documentation and undertakes other administrative/management tasks as required. 1.9 Participates in departmental and other meetings as required to meet organisational and service objectives. 1.10 Develops and seeks to implement change utilising expert clinical knowledge through research and evidence based best practice. 1.11 Monitors and maintains availability of consumable stock. 1.12 Complies with and demonstrates a positive commitment to Regulations, Acts and Policies relevant to nursing including the Code of Ethics for Nurses in Australia, the Code of Conduct for Nurses in Australia, the National Competency Standards for the Registered Nurse and the Poisons Act 2014 and Medicines and Poisons Regulations 2016. 1.13 Promotes and participates in team building and decision making. 1.14 Responsible for the clinical supervision of nurses at Level 1 and/or Enrolled Nurses/ Assistants in Nursing under their supervision.

  • Studies The clinical, pre-clinical and other studies and tests conducted by or on behalf of or sponsored by the Company or its subsidiaries that are described or referred to in the Registration Statement, the Pricing Disclosure Package and the Prospectus were and, if still pending, are being conducted in accordance in all material respects with all statutes, laws, rules and regulations, as applicable (including, without limitation, those administered by the FDA or by any foreign, federal, state or local governmental or regulatory authority performing functions similar to those performed by the FDA). The descriptions of the results of such studies and tests that are described or referred to in the Registration Statement, the Pricing Disclosure Package and the Prospectus are accurate and complete in all material respects and fairly present the published data derived from such studies and tests, and each of the Company and its subsidiaries has no knowledge of other studies or tests the results of which are materially inconsistent with or otherwise call into question the results described or referred to in the Registration Statement, the Pricing Disclosure Package and the Prospectus. Except as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, neither the Company nor its subsidiaries has received any notices or other correspondence from the FDA or any other foreign, federal, state or local governmental or regulatory authority performing functions similar to those performed by the FDA with respect to any ongoing clinical or pre-clinical studies or tests requiring the termination or suspension of such studies or tests. For the avoidance of doubt, the Company makes no representation or warranty that the results of any studies, tests or preclinical or clinical trials conducted by or on behalf of the Company will be sufficient to obtain governmental approval from the FDA or any foreign, state or local governmental body exercising comparable authority.

  • Study An application for leave of absence for professional study must be supported by a written statement indicating what study or research is to be undertaken, or, if applicable, what subjects are to be studied and at what institutions.

  • Clinical Trials The studies, tests and preclinical and clinical trials conducted by or on behalf of, or sponsored by, the Company, or in which the Company has participated, that are described in the Registration Statement or the Prospectus, or the results of which are referred to in the Registration Statement or the Prospectus, were and, if still pending, are being conducted in all material respects in accordance with protocols, procedures and controls pursuant to, where applicable, accepted professional and scientific standards for products or product candidates comparable to those being developed by the Company and all applicable statutes, rules and regulations of the FDA, the EMA, Health Canada and other comparable regulatory agencies outside of the U.S. to which they are subject, including, without limitation, 21 C.F.R. Parts 50, 54, 56, 58, 312, and 812; the descriptions of the results of such studies, tests and trials contained in the Registration Statement or the Prospectus do not contain any misstatement of a material fact or omit a material fact necessary to make such statements not misleading; the Company has no knowledge of any studies, tests or trials not described in the Registration Statement or the Prospectus the results of which reasonably call into question in any material respect the results of the studies, tests and trials described in the Registration Statement or Prospectus; and the Company has not received any notices or other correspondence from the FDA, EMA, Health Canada or any other foreign, state or local governmental body exercising comparable authority or any Institutional Review Board or comparable authority requiring or threatening the termination, suspension or material modification of any studies, tests or preclinical or clinical trials conducted by or on behalf of, or sponsored by, the Company or in which the Company has participated, and, to the Company’s knowledge, there are no reasonable grounds for the same. Except as disclosed in the Registration Statement and the Prospectus, there has not been any violation of law or regulation by the Company in its respective product development efforts, submissions or reports to any regulatory authority that could reasonably be expected to require investigation, corrective action or enforcement action.